scholarly journals CCL2 in the Circulation Predicts Long-Term Progression of Interstitial Lung Disease in Patients With Early Systemic Sclerosis: Data From Two Independent Cohorts

2017 ◽  
Vol 69 (9) ◽  
pp. 1871-1878 ◽  
Author(s):  
Minghua Wu ◽  
Murray Baron ◽  
Claudia Pedroza ◽  
Gloria A. Salazar ◽  
Jun Ying ◽  
...  
Keyword(s):  
Systemic Sclerosis ◽  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Early Systemic Sclerosis

scholarly journals Does C-Reactive Protein Predict the Long-Term Progression of Interstitial Lung Disease and Survival in Patients With Early Systemic Sclerosis?

2013 ◽  
Vol 65 (8) ◽  
pp. 1375-1380 ◽  
Author(s):  
Xiaochun Liu ◽  
Maureen D. Mayes ◽  
Claudia Pedroza ◽  
Hilda T. Draeger ◽  
Emilio B. Gonzalez ◽  
...  
Keyword(s):  
Systemic Sclerosis ◽  
Interstitial Lung Disease ◽  
Lung Disease ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Early Systemic Sclerosis

Tocilizumab Prevents Progression of Early Systemic Sclerosis Associated Interstitial Lung Disease

2021 ◽  
Author(s):  
David Roofeh ◽  
Celia J F Lin ◽  
Jonathan Goldin ◽  
Grace Hyun Kim ◽  
Daniel E Furst ◽  
...  
Keyword(s):  
Systemic Sclerosis ◽  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Early Systemic Sclerosis

Incidence and predictors of interstitial lung disease (ILD) in Thai patients with early systemic sclerosis: Inception cohort study

2015 ◽  
Vol 26 (4) ◽  
pp. 588-593 ◽  
Author(s):  
Suparaporn Wangkaew ◽  
Juntima Euathrongchit ◽  
Pittaporn Wattanawittawas ◽  
Nuntana Kasitanon ◽  
Worawit Louthrenoo
Keyword(s):  
Cohort Study ◽  
Systemic Sclerosis ◽  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Inception Cohort ◽  
Early Systemic Sclerosis

scholarly journals Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort

2010 ◽  
Vol 12 (5) ◽  
pp. R166 ◽  
Author(s):  
Shervin Assassi ◽  
Roozbeh Sharif ◽  
Robert E Lasky ◽  
Terry A McNearney ◽  
Rosa M Estrada-Y-Martin ◽  
...  
Keyword(s):  
Longitudinal Study ◽  
Systemic Sclerosis ◽  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Prospective Longitudinal Study ◽  
Prospective Longitudinal ◽  
Early Systemic Sclerosis

scholarly journals Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database

2020 ◽  
pp. annrheumdis-2020-217455 ◽  
Author(s):  
Anna-Maria Hoffmann-Vold ◽  
Yannick Allanore ◽  
Margarida Alves ◽  
Cathrine Brunborg ◽  
Paolo Airó ◽  
...  
Keyword(s):  
Systemic Sclerosis ◽  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Organ Damage ◽  
Disease Course ◽  
Lung Function Decline ◽  
Mixed Effect ◽  
Progression Patterns

ObjectivesTo identify overall disease course, progression patterns and risk factors predictive for progressive interstitial lung disease (ILD) in patients with systemic sclerosis-associated ILD (SSc-ILD), using data from the European Scleroderma Trials And Research (EUSTAR) database over long-term follow-up.MethodsEligible patients with SSc-ILD were registered in the EUSTAR database and had measurements of forced vital capacity (FVC) at baseline and after 12±3 months. Long-term progressive ILD and progression patterns were assessed in patients with multiple FVC measurements. Potential predictors of ILD progression were analysed using multivariable mixed-effect models.Results826 patients with SSc-ILD were included. Over 12±3 months, 219 (27%) showed progressive ILD: either moderate (FVC decline 5% to 10%) or significant (FVC decline >10%). A total of 535 (65%) patients had multiple FVC measurements available over mean 5-year follow-up. In each 12-month period, 23% to 27% of SSc-ILD patients showed progressive ILD, but only a minority of patients showed progression in consecutive periods. Most patients with progressive ILD (58%) had a pattern of slow lung function decline, with more periods of stability/improvement than decline, whereas only 8% showed rapid, continuously declining FVC; 178 (33%) experienced no episode of FVC decline. The strongest predictive factors for FVC decline over 5 years were male sex, higher modified Rodnan skin score and reflux/dysphagia symptoms.ConclusionSSc-ILD shows a heterogeneous and variable disease course, and thus monitoring all patients closely is important. Novel treatment concepts, with treatment initiation before FVC decline occurs, should aim for prevention of progression to avoid irreversible organ damage.

Sign in / Sign up

Export Citation Format

Share Document